AIDS Malignancy Consortium (AMC)

项目摘要/摘要 艾滋病恶性联盟(AMC)成立于1995年，一直走在前列 年恶性肿瘤防治干预措施的临床评价 人类免疫缺陷病毒(PLWH)携带者。AMC还研究了 在PLWH的临床试验背景下的癌症和癌前病变，提供了新的 关于进一步提高癌症治疗和预防水平的见解。AMC已经进行了 涉及8700多名艾滋病毒患者的100多项临床试验、调查和实验室研究- 自成立以来的相关癌症和癌前病变，包括应用 精确疗法和免疫疗法，影响了PLWH和 癌症。AMC已在美国、非洲、 和拉丁美洲唯一有资格履行其使命，创建了一个翻译网络 支持AMC临床试验的科学家及其研究实验室，并开发了一种 培养了新一代医生和科学家的职业提升计划 在艾滋病毒相关癌症方面拥有独特的专业知识。将AMC扩展到分地区的临床试验地点 撒哈拉非洲和拉丁美洲旨在解决世界上 艾滋病毒和癌症的流行大幅增加，从而放大了潜在的临床 其工作对全球范围的影响。AMC还积极接触PLWH和癌症幸存者 在其科学规划和社区宣传中，以确定社区的需求， 并传播有关AMC及其已完成和正在进行的研究的信息。这个 许多主要临床医生和临床研究人员、实验室科学家以及 社区代表使AMC成为世界上主要的临床试验小组 致力于改善这一人群中癌症的治疗和预防。我们建议 为了继续和扩大我们在这些领域的国内和国际临床试验工作， 包括锚定试验；锚定是一项大型随机研究，调查 高级别肛门鳞状上皮内病变的常规筛查和治疗 预防侵袭性肛门癌的发展和发病率和死亡率的目标 与其诊断和治疗相关，从而建立新的诊断和治疗 治疗范例。

PROJECT SUMMARY/ABSTRACT The AIDS Malignancy Consortium (AMC) was established in 1995 and has been at the forefront of the clinical evaluation of interventions for the treatment and prevention of malignancies in people living with the human immunodeficiency virus (PLWH). AMC also studies the biology of cancers and precancerous lesions in PLWH in the context of its clinical trials, providing new insights on further improving the treatment and prevention of cancer. The AMC has conducted over 100 clinical trials, surveys and laboratory studies involving over 8700 patients with HIV- associated cancers and precancerous lesions since its inception, including application of precision therapeutics and immunotherapy, impacting the standard of care for PLWH and cancer. AMC has established a network of 42 core clinical trial sites in the United States, Africa, and Latin America uniquely qualified carry out its mission, created a network of translational scientists and their research laboratories that support AMC clinical trials, and developed a career enhancement program that has fostered a new generation of physicians and scientists with unique expertise in HIV-associated cancers. Expansion of AMC to clinical trials sites in sub- Saharan Africa and Latin America is designed to address regions of the world where the epidemic of HIV and cancer has grown substantially, thereby amplifying the potential clinical impact of its work to a global scale. AMC has also actively engaged PLWH and cancer survivors in its scientific planning and community outreach in order to identify the needs of the community, and disseminate information about AMC and its completed and ongoing research. The participation of many of the key clinicians and clinical researchers, laboratory scientists, and community representatives has made AMC the principal clinical trials group in the world dedicated to improving the treatment and prevention of cancers in this population. We propose to continue and expand our domestic and international clinical trials work in these areas, including the ANCHOR trial; ANCHOR is a large randomized study investigating the role of routine screening for and treatment of high-grade anal squamous intraepithelial lesions, with the goal of preventing development of invasive anal cancer and the morbidity and mortality associated with its diagnosis and treatment, thereby establishing new diagnostic and therapeutic paradigm.